GSK and the Fleming Initiative have launched six major new research programmes aiming to combat antimicrobial resistance (AMR). 

The six ‘Grand Challenges’ will bring together scientific expertise and the latest technologies, including AI, to find new ways to slow the progress of AMR. The project has been backed by £45 million ($59 million) of funding from GSK, with all programmes fully funded for three years.  

The Fleming Initiative is a groundbreaking collaboration between Imperial College London and Imperial College Healthcare NHS Trust, uniting researchers, policymakers, clinicians, and public and commercial partners. The Fleming Initiative works to provide solutions to AMR on a global scale and previously announced a partnership with GSK in 2024. 

“In the 12 months since we announced our landmark partnership between GSK and the Fleming Initiative, a huge amount of progress has been made,” said Professor Lord Ara Darzi, Executive Chair of the Fleming Initiative. 

“Through our convening power, we have the world-leading expertise, facilities, capacity and vision in place to be able to launch these ambitious Grand Challenges. 

“Today, in the shadow of 80 years since the Nobel prize for the discovery of penicillin, we’re delighted to see this research progress. We hope this research will be a beacon for the global scientific community and highlight the urgent need for collaborative efforts to tackle the rising global threat of antimicrobial resistance.” 

‘Grand Challenges’ aim to tackle threat of AMR

According to the recent WHO GLASS Report, the global AMR picture is worsening, with around one in six laboratory bacterial infections caused by bacteria resistant to antibiotics. Annual deaths associated with AMR are predicted to rise by 74.5% from 4.71 million in 2021 to 8.22 million in 2050. 

One of the ‘Grand Challenges’ aims to discover new antibiotics for Gram-negative bacterial infections. Gram-negative bacteria, one of the most concerning threats to human health, have a complex cell envelope defence system which prevents antibiotics from accumulating inside the cell, with efflux pumps ejecting antibiotics which do enter. 

Other ‘Grand Challenges’ include accelerating the discovery of new drugs to combat fungal infections, understanding the immune system response to drug-resistant bacteria, and predicting how drug-resistant pathogens emerge and spread. 

The initiative will fund around 50 dedicated, multi-disciplinary scientific, clinical and academic roles, with work largely based in Imperial College London facilities in the UK. 

“I’m delighted to combine GSK’s leadership in antimicrobial science with world-leading research at Imperial College London,” Tony Wood, Chief Scientific Officer at GSK, added.  

“Together, with scaled datasets, emerging drug modalities and AI-driven models, we will open up new approaches for the discovery of novel antibiotics as well as anticipate and outpace the development of resistance to transform the treatment and prevention of serious infections.” 

The programmes are expected to get underway in early 2026.  

 

Bruno Quinney, Content Team, DDW